Industries
Pharma: what your operating records are worth to AI research
A pharma company's unit of work is the batch record or the study milestone its teams complete, not the identity of a trial subject. Subject identifiers and patient-level clinical rows are excluded. Manufacturing and quality workflows are the part a license can cover.
Up to $150K · $0 cost · 3 days
| Fact | Detail |
|---|---|
| Unit of work | batch record or study milestone |
| First exclusion | trial-subject identifiers |
| First rule | Batch production and control records shall be prepared for each batch of drug product produced and shall include complete information relating to the production and control of each batch. eCFR |
| Second rule | Any production, control, or distribution record required under 21 CFR Part 211 and specifically associated with a batch of a drug product shall be retained for at least 1 year after the expiration date of the batch. For certain over-the-counter drug products that lack expiration dating because they meet the exemption in 21 CFR 211.137, the period is 3 years after distribution of the batch. eCFR |
What Pharma operating records look like
Pharma operating records are the batch record or study milestone a team completes, and they are not the identity of a trial subject.
Releasing a batch records the checks, the yield, and who signed the release. Recording a deviation records what failed and how it was closed. Those are manufacturing and quality events. A patient chart, a subject id, and a row of lab values tied to a person are a different file.
Other sectors are grouped under company data licensing by industry.
The license itself is explained in how to sell company data to AI companies.
Workflows in Pharma that AI research can learn from
Releasing a batch, recording a deviation, and advancing a study milestone are three trails in a batch record or study milestone, and none of them is a patient chart.
- releasing a batch
- recording a deviation
- advancing a study milestone
Advancing a study milestone records the protocol step and the date the team called it done, not the enrollment roster. The full batch history matters because a release signature alone hides the deviation.
For a related sector's records, read healthcare company data for AI research or manufacturing company data for AI research.
Systems Pharma companies usually run
Mail, tickets, and chat hold the quality trail around a batch record or study milestone. A quality management system is named only as plain text.
Microsoft 365 holds the batch packet and the study memo. Jira holds the deviation ticket. Slack holds the quality question. The quality management system is the system of record and is listed as plain text.
| System | Category | Why it holds this sector's work |
|---|---|---|
| Microsoft 365 | Email and collaboration | Batch packets and study memos sit in mail and documents. |
| Jira | Project or workflow | Deviations are tracked as tickets. |
| Slack | Chat | Quality questions between shifts sit in chat. |
| quality management system | Industry system | The controlled batch and study record sits in the quality management system. |
What a Pharma license leaves out
Trial-subject identifiers and patient-level clinical rows stay out, even when a batch record or study milestone points at the study they came from.
- trial-subject identifiers
- patient-level clinical rows
Trial-subject identifiers include the subject code when it can be tied back to a person, and the name. Patient-level clinical rows include individual lab results and adverse-event narratives that identify someone. Summaries that do not identify a person are a different object.
The details that never leave any company are listed in what is never shared.
Rules cited for Pharma records
Each note on a batch record or study milestone quotes a public drug-manufacturing or research source, and none of them is a clearance for a license.
The notes come from drug-manufacturing and clinical-research rules, not from the health-privacy notes used for a clinic. A batch record is not a chart.
| Rule | What the source says | Source |
|---|---|---|
| 21 CFR 211.188 — Batch production and control records | Batch production and control records shall be prepared for each batch of drug product produced and shall include complete information relating to the production and control of each batch. | eCFR |
| 21 CFR 211.180(a) — Retention of batch records | Any production, control, or distribution record required under 21 CFR Part 211 and specifically associated with a batch of a drug product shall be retained for at least 1 year after the expiration date of the batch. For certain over-the-counter drug products that lack expiration dating because they meet the exemption in 21 CFR 211.137, the period is 3 years after distribution of the batch. | eCFR |
| 21 CFR 211.192 — Production record review | The quality control unit shall review and approve all drug product production and control records, including packaging and labeling, before a batch is released or distributed. Any unexplained discrepancy, or any failure of a batch or its components to meet specifications, shall be thoroughly investigated, and a written record of the investigation shall include the conclusions and followup. | eCFR |
| 21 CFR 11.1(b) — Electronic records scope | 21 CFR Part 11 applies to records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted under records requirements in Food and Drug Administration regulations. It also applies to electronic records submitted to the agency under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. It does not apply to paper records that are, or have been, transmitted by electronic means. | eCFR |
| 21 CFR 50.1 — Scope of human-subject protections | 21 CFR Part 50 applies to clinical investigations regulated by the Food and Drug Administration under sections 505(i) and 520(g) of the Federal Food, Drug, and Cosmetic Act, and to clinical investigations that support applications for research or marketing permits for products the agency regulates, including drugs for human use and biological products for human use. | eCFR |
| 21 CFR 50.20 — Informed consent | Except as provided in 21 CFR 50.22, 50.23, and 50.24, no investigator may involve a human being as a subject in research covered by these regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative. | eCFR |
Wind-down specifics for Pharma
Closing a plant or a study does not turn subject identities into a licensable archive. Keep the batch record or study milestone, and leave the subject list out.
Export the batch packet and the milestone log. Leave the subject list and the patient-level tables out. Ending a study does not convert those tables into an operating record.
- Export the batch packet and the milestone log.
- Leave the subject list and patient-level tables out.
- Ending a study does not convert those tables into an operating record.
General information only. This is not legal, tax or financial advice.
Related
- Industries
What operating records look like by sector, and what is left out.
- How to sell company data
How to sell or license company data to AI companies, and which route fits.
- What's shared
Which records can be licensed, which details never leave, and what you approve.
- Eligibility
Staff, records, daily-use systems, and the right to license, plus a checker.
- Estimate
US payout bands by staff at peak, and the estimator that uses them.
- Healthcare
Care-episode workflow, with patient identifiers left out.
- Manufacturing
Work orders, with worker names left out.
Questions about pharma company data for AI research
Which trial-subject identifiers never leave a pharma company in a license?
Trial-subject identifiers never leave a pharma company in a license. That includes the name and a subject code when it can be tied back to a person. Patient-level clinical rows stay out with them: individual lab results and adverse-event narratives that identify someone. The batch record or study milestone can be described. The enrollment roster cannot.
Is a batch record the same kind of file as a patient chart?
No. A batch record or study milestone is a manufacturing and quality event: the checks, the yield, the deviation, and the protocol step a team called done. A patient chart names a person. Releasing a batch and recording a deviation are not a diagnosis. The two files do not substitute for each other, and the subject list does not become a batch record because a study ended.
Which quality and lab systems should a pharma company inventory first?
Inventory Microsoft 365 for the batch packet and the study memo, Jira for the deviation ticket, and Slack for the quality question between shifts. The quality management system is the system of record and is listed as plain text. Start there, and leave patient-level tables out of any export. A lab instrument export that still has subject identifiers is not the milestone log.
Can a drug sponsor treat a sector write-up as a regulatory clearance?
No. A drug sponsor cannot treat a sector write-up as a regulatory clearance. Notes quote public drug-manufacturing and research sources. They do not clear a license, and they do not say a batch file meets a clinical rule written for a chart. The fit check still decides. Subject identifiers stay out either way.
Sources
- eCFR. 21 CFR 211.188 — Batch production and control records. Checked 2026-11-04
- eCFR. 21 CFR 211.180(a) — Retention of batch records. Checked 2026-11-04
- eCFR. 21 CFR 211.192 — Production record review. Checked 2026-11-04
- eCFR. 21 CFR 11.1(b) — Electronic records scope. Checked 2026-11-04
- eCFR. 21 CFR 50.1 — Scope of human-subject protections. Checked 2026-11-04
- eCFR. 21 CFR 50.20 — Informed consent. Checked 2026-11-04